Publication & Citation Trends
Publications
0 total
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
Cited by 1
Semantic Scholar
Abstract CT233: A phase 2b study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for EGFR-mutated non-small cell lung cancer (NSCLC): COPERNICUS
Cited by 0
Semantic Scholar
Research Topics
Lipoproteins and Cardiovascular Health
(15)
Diabetes, Cardiovascular Risks, and Lipoproteins
(9)
Antiplatelet Therapy and Cardiovascular Diseases
(5)
Lung Cancer Treatments and Mutations
(4)
Prostate Cancer Treatment and Research
(4)
Affiliations
Johnson & Johnson (United States)
Janssen (Belgium)
Inserm
Délégation Paris 7
Université Paris Cité